Amryt Pharma has completed the acquisition of Aegerion Pharmaceuticals. The deal, which comes after Aegerion filed for Chapter 11 bankruptcy, gives Amryt near-full control of two commercial drugs that could provide revenues to support its protracted attempt to get AP101 to market.
Aegerion won FDA approval for cholesterol drug Juxtapid late in 2012 and completed a $325 million convertible debt offering two years later. Shortly after the debt offering, Aegerion paid AstraZeneca $325 million for leptin deficiency drug Myalept. The actions gave Aegerion two commercial drugs, but neither proved to be a big enough success to support the debt it took on.
Amryt picked up the European rights to Juxtapid from Aegerion late in 2016 in a deal that lacked an upfront component. And earlier this year, it put together an all-stock deal designed to free Aegerion from debt and transfer ownership of the business to Amryt.
The completion of that deal leaves Amryt with the near-global rights to Juxtapid and Myalept. Last year, the products generated sales of $136.5 million. Amryt will look to grow that figure, although it faces patent expirations in the coming years that may limit the longer-term prospects of the drugs.
By then, Amryt may have brought its lead candidate, epidermolysis bullosa treatment AP101, to market. A pivotal trial of the drug has taken longer than expected, with Amryt pushing back the targeted readout by about a year to buy it time to enroll more patients than initially expected.
Amryt expects to deliver data next year, and, under the terms of its deal with Aegerion, will pay out if the drug comes to market in the U.S. or Europe before July 2022. The Aegerion deal also features a payment tied to the sales AP101 generates before the start of July 2024.
By Nick Paul Taylor
Source: Fierce Biotech
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
